A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel in combination with Trastuzumab for stage I HER2-positive breast cancer (ATEMPT Trial)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
June 1, 2014
End Date
December 31, 2021
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
June 1, 2014
End Date
December 31, 2021